Kenneth Cheung/iStock Unreleased via Getty Images
Listen below or on the go via Apple Podcasts and Spotify
Meta to acquire Singapore-based Manus for AI agent capabilities. (00:20) Boeing (BA) scores $8.6B contract to build aircraft for Israel Air Force. (01:09) Novo Nordisk (NVO) cuts Wegovy price in China. (01:56)
This is an abridged transcript.
Meta (META) said on Monday that it will buy Manus—a Singapore-based AI startup specializing in general-purpose AI agents—to integrate advanced AI into consumer and business products.
The financial terms of the deal were not disclosed. Currently based in Singapore, Manus was originally founded in China by Butterfly Effect Technology before relocating its headquarters.
The startup achieved a $125 million annual revenue run rate shortly after launching its subscription-based AI agent for tasks like research, coding, data analysis, resume screening, and stock analysis. Manus is set to continue operating from Singapore.
The acquisition aligns with Meta (META) CEO Mark Zuckerberg’s priority on AI infrastructure, data centers, and monetization beyond metaverse efforts. This marks the company’s fifth AI-related acquisition in 2025 and signals the company’s intensifying focus on agentic AI skillset development.
Boeing (BA) was awarded a contract for as much as $8.6 billion from the U.S. Air Force on Monday to build F-15 fighter jets for the Israeli Air Force.
The contract “provides for the design, integration, instrumentation, test, production and delivery of 25 new F-15IA aircraft for the Israeli Air Force with an option for an additional 25 F-15IA aircraft,” with the work to be performed in St. Louis, Mo., and expected to be completed by year-end 2035. the Pentagon said.
Separately, the U.S. Air Force said Boeing (BA) received a modification to a previous award for depot maintenance services and supply management in Oklahoma City, raising the award to $4.2 billion from $1.5 billion.
Novo Nordisk (NVO) has reduced the price of its GLP-1 medication Wegovy (semaglutide) in China, where it is approved for weight reduction.
List prices for the two highest dosage strengths were cut by nearly 50% in several provinces, according to local media, Bloomberg reported.
The move comes as semaglutide’s patent in China will expire in March 2026, setting the stage for a flood of semaglutide generics to hit the market.
Earlier this year, an estimate projected that 65% of the Chinese population could be considered obese by 2030.
What’s Trending on Seeking Alpha
SA Asks: Would SpaceX stock be a good investment?
Silver slammed in biggest one-day drop since 2021, gold also plunges
Samsung wins annual U.S. approval for chipmaking tool shipments to China – report
Dow, S&P and Nasdaq futures are in the green. Crude oil is up 0.5% at $58/barrel. Bitcoin is up 0.8% at $87,000. Gold is up 0.8% at $4,369.
The FTSE 100 is up 0.2% and the DAX is up 0.5%.
The biggest movers for the day premarket: New Era Energy & Digital (NUAI) -4.83% – Shares slid, attributed to the fallout from a civil complaint filed by the State of New Mexico Attorney General and the New Mexico Oil Conservation Division.
On today’s economic calendar:
